Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

8.3%

3 terminated out of 36 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

7%

2 of 27 completed with results

Key Signals

2 with results90% success

Data Visualizations

Phase Distribution

34Total
Not Applicable (6)
Early P 1 (1)
P 1 (26)
P 4 (1)

Trial Status

Completed27
Terminated3
Unknown3
Not Yet Recruiting1
Recruiting1
Withdrawn1

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 27 completed trials

Clinical Trials (36)

Showing 20 of 20 trials
NCT04080895Phase 1TerminatedPrimary

Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects

NCT07282093Phase 1RecruitingPrimary

Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

NCT04350502Not ApplicableCompleted

Pharmacokinetics and Pleural Fluid Penetration of Amoxicillin and Clavulanic Acid in Patients With Pleural Infections

NCT03076151Phase 4Completed

Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation

NCT04531150Phase 1CompletedPrimary

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

NCT06679556Phase 1CompletedPrimary

Phase 1 Pharmacokinetic Study of Minoxidil SL Tablets

NCT06471023Not ApplicableCompleted

A Pharmacokinetic Study of Single Oral Doses of Six Different Vitamin C Product Forms

NCT06378125Phase 1Completed

Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes

NCT06344858Completed

Characterization of the Temporal Profile of the Anti-nociceptive Effect of Ketamine Bolus Measured With ANI

NCT06524674Not ApplicableCompleted

Clinical Study to Compare the Effect of an Oral Rehydration Solution on the Rate of Absorption of Functional Ingredients

NCT05938608Phase 1Withdrawn

A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body

NCT06126562Phase 1CompletedPrimary

A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects

NCT03437265Phase 1CompletedPrimary

A Pharmacokinetic Study of PLENVU® in Healthy Subjects

NCT04959110Not ApplicableCompleted

Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT

NCT05258474Phase 1Completed

Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM)

NCT04820049Phase 1Completed

F573 Ia Clinical Trial

NCT05367011Not Yet Recruiting

Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU

NCT04735913Early Phase 1Unknown

Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults

NCT03059511Phase 1TerminatedPrimary

Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants

NCT04617509Phase 1CompletedPrimary

A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248

Scroll to load more

Research Network

Activity Timeline